ALK Reports Peanut Allergy Tablet Trial Data
Phase II results from the ALLIANCE trial were presented at the ACAAI 2026 annual meeting in Phoenix, Arizona.
Updated on Nov. 12, 2026 in Allergies
ALK presented phase II data from its ALLIANCE trial of a once-daily peanut sublingual immunotherapy tablet at the ACAAI 2026 meeting. The study enrolled 150 patients aged 4 to 65 and compared two doses with placebo.
Why it matters
Treatment options for peanut allergy remain limited, and more than 10 million people in Europe, the USA and Canada have the condition. ALK plans to advance the investigational tablet into phase III to see whether longer treatment can improve response.
The phase II results are a randomized trial comparing two doses against placebo, with efficacy observed after six months of maintenance and 216 participants enrolled across all phases. The phase III study will test whether longer treatment improves response, and no specific efficacy percentage has been reported.
The players
ALK
ALK is a Denmark-headquartered allergy immunotherapy company with around 2,800 employees worldwide that develops allergen treatments.
The details
Efficacy was observed across all age groups, treatment-related discontinuations were low, and no treatment-related anaphylaxis or serious adverse events were reported. The ALLIANCE trial began in 2022 and the data were presented at the ACAAI Annual Scientific Meeting, with a Product Theater and poster presentations scheduled for 13 November 2026.
Timeline
2022: ALLIANCE trial initiated.
12-16 November 2026: ACAAI Annual Scientific Meeting in Phoenix, Arizona.
13 November 2026: Product Theater and poster presentations of ALLIANCE data.
Big Picture
The ALLIANCE program moves ALK's peanut sublingual tablet from phase II data toward a planned phase III study that will test longer treatment duration. Its progress matters for the limited set of peanut allergy options currently available.
If approved, the tablet would offer a once-daily sublingual option for people with peanut allergy, a condition affecting more than 3 million children and adolescents in Europe, the USA and Canada. The reported trial found no treatment-related anaphylaxis or serious adverse events, though phase III results will determine broader use.
The takeaway
Peanut allergy treatment is moving toward daily sublingual tablets, but longer-term phase III data will determine whether the approach works for more patients. Anyone managing peanut allergy should follow their allergist's guidance rather than wait for new therapies.
What happens next
ALK plans to advance its investigational peanut tablet into a phase III study building on the ALLIANCE results.
Further reading
For background on the condition, see Allergies.
